Latest & greatest articles for proton pump inhibitors

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on proton pump inhibitors or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on proton pump inhibitors and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for proton pump inhibitors

61. Are higher doses of proton pump inhibitors better in acute peptic bleeding? Full Text available with Trip Pro

Are higher doses of proton pump inhibitors better in acute peptic bleeding? Although there is broad consensus about the benefits of proton pump inhibitors in acute upper peptic bleeding, there is still controversy over their optimal dosing. Searching in Epistemonikos database, which is maintained by screening 30 databases, we identified six systematic reviews including 27 randomized trials addressing this question. We combined the evidence using meta-analysis and generated a summary of findings (...) table following the GRADE approach. We concluded high-dose proton pump inhibitors probably result in little or no difference in re-bleeding rate or mortality. The risk/benefit and cost/benefit balance probably favor use of low-doses.

2017 Medwave

62. Ten-Day Quadruple Therapy Comprising Proton Pump Inhibitor, Bismuth, Tetracycline, and Levofloxacin is More Effective than Standard Levofloxacin Triple Therapy in the Second-Line Treatment of Helicobacter pylori Infection: A Randomized Controlled Trial (Abstract)

Ten-Day Quadruple Therapy Comprising Proton Pump Inhibitor, Bismuth, Tetracycline, and Levofloxacin is More Effective than Standard Levofloxacin Triple Therapy in the Second-Line Treatment of Helicobacter pylori Infection: A Randomized Controlled Trial Proton pump inhibitor (PPI)-amoxicillin-fluoroquinolone triple therapy is recommended as a second-line treatment of Helicobacter pylori infection in the Maastricht V/Florence Consensus Report. However, the eradication rate of this standard

2017 EvidenceUpdates

63. Gastrointestinal symptoms associated with gastroesophageal reflux disease, and their relapses after treatment with proton pump inhibitors: A systematic review. Full Text available with Trip Pro

Gastrointestinal symptoms associated with gastroesophageal reflux disease, and their relapses after treatment with proton pump inhibitors: A systematic review. Gastroesophageal reflux disease (GERD) is a common functional gastrointestinal disorder with significant effects on the quality of life. The burden of GERD is soaring in Asia. Preventing symptom relapse is a therapeutic goal in GERD patients. Since proton pump inhibitors (PPI) are the first-line treatment of GERD, drug failure has become

2017 Electronic physician

64. Concomitant proton pump inhibitor use does not reduce the efficacy of elbasvir/grazoprevir: A pooled analysis of 1,322 patients with hepatitis C infection Full Text available with Trip Pro

Concomitant proton pump inhibitor use does not reduce the efficacy of elbasvir/grazoprevir: A pooled analysis of 1,322 patients with hepatitis C infection Concomitant proton pump inhibitor (PPI) use reduces plasma concentrations of certain nonstructural protein 5A inhibitors, which are key components of modern hepatitis C infection (HCV) treatments. These reduced concentrations may decrease efficacy, leading to challenging treatment failures due to the development of resistance-associated

2017 Hepatology communications

65. Efficacy and Safety of Direct-acting Antivirals in Hepatitis C Virus-infected Patients Taking Proton Pump Inhibitors Full Text available with Trip Pro

Efficacy and Safety of Direct-acting Antivirals in Hepatitis C Virus-infected Patients Taking Proton Pump Inhibitors Background and Aims: Direct-acting antiviral (DAA) therapy is the cornerstone of the treatment of chronic hepatitis C virus (HCV) infection. Eradication of HCV, predicted by the attainment of a sustained virologic response (SVR) 12 weeks following DAA therapy, is the goal of this treatment. Interestingly, recent studies have reported the possible association between HCV-infected (...) patients with DAA therapy concomitant use of proton pump inhibitors (PPIs) and lower odds of achieving SVR. This meta-analysis was conducted to summarize all available data and to estimate this potential association. Methods: Comprehensive literature review was conducted by first searching the Medline and Embase databases through March 2017 to identify all studies that investigated the safety and efficacy of DAAs in patients with HCV infection taking PPIs versus those without PPIs. Adjusted point

2017 Journal of clinical and translational hepatology

66. No Association Between Proton Pump Inhibitor Use and Risk of Alzheimer's Disease Full Text available with Trip Pro

No Association Between Proton Pump Inhibitor Use and Risk of Alzheimer's Disease The objective of the study was to investigate whether proton pump inhibitor (PPI) use is associated with an increased risk of clinically verified Alzheimer's disease (AD).A Finnish nationwide nested case-control study MEDALZ includes all community-dwelling individuals with newly diagnosed AD during 2005-2011 (N=70,718), and up to four age-, sex-, and region of residence-matched comparison individuals for each case

2017 EvidenceUpdates

67. Gastric Ulcer Complications after the Introduction of Proton Pump Inhibitors into Clinical Routine: 20-Year Experience Full Text available with Trip Pro

Gastric Ulcer Complications after the Introduction of Proton Pump Inhibitors into Clinical Routine: 20-Year Experience The aim of this study was to analyze the admissions and the management of peptic ulcer disease (PUD) in a tertiary care surgical center.We evaluated the medical records of all patients admitted to the University Hospital of Tübingen, Germany, for treatment of PUD during 1989-2008. Patients were included into the study if the diagnosis was verified endoscopically or surgically (...) . Annual number of admissions, length of hospitalization, mortality rate, age, rate of non-steroidal anti-inflammatory drugs (NSAIDs) and proton pump inhibitor (PPI) medication, rate of Helicobacter pylori infection, and complications of PUD and surgery performed were recorded. Data were analyzed by descriptive analyses, Pearson's chi-square test, and regression analysis.This study included 614 admissions. The number of annual admissions (31 ± 12), the length of hospitalization (9 ± 3 days

2017 Visceral medicine

68. Deprescribing proton pump inhibitors

Deprescribing proton pump inhibitors 354 Canadian Family Physician • Le Médecin de famille canadien | Vol 63: may • mai 2017 Clinical Practice Guidelines Deprescribing proton pump inhibitors Evidence-based clinical practice guideline Barbara Farrell PharmD ACPR FCSHP Kevin Pottie MD CCFP MClSc FCFP Wade Thompson Taline Boghossian ACPR Lisa Pizzola MSc Farah Joy Rashid ACPR Carlos Rojas-Fernandez PharmD Kate Walsh ACPR Vivian Welch PhD Paul Moayyedi MB ChB PhD MPH Abstract Objective To develop (...) an evidence-based guideline to help clinicians make decisions about when and how to safely taper or stop proton pump inhibitors (PPIs); to focus on the highest level of evidence available and seek input from primary care professionals in the guideline development, review, and endorsement processes. Methods Five health professionals (1 family physician, 3 pharmacists, and 1 gastroenterologist) and 5 nonvoting members comprised the overall team; members disclosed conflicts of interest. The guideline process

2017 CPG Infobase

69. Proton Pump Inhibitor and Histamine-2 Receptor Antagonist Use and Iron Deficiency Full Text available with Trip Pro

Proton Pump Inhibitor and Histamine-2 Receptor Antagonist Use and Iron Deficiency Proton pump inhibitors (PPIs) and histamine-2 receptor antagonists (H2RAs) suppress gastric acid production, which can inhibit iron absorption. However, few data exist regarding whether these medications increase the risk of clinical iron deficiency.A community-based case-control study evaluated the association between acid-suppressing medication use and the subsequent risk of iron deficiency. It contrasted 77,046 (...) day for at least 10 years (odds ratio, 4.27; 95% CI, 2.53-7.21). No similar strong associations were found for other commonly used prescription medications.Among patients without known risk factors for iron deficiency, gastric acid inhibitor use for ≥2 years was associated with an increased subsequent risk of iron deficiency. The risk increased with increasing potency of acid inhibition and decreased after medication discontinuation.Copyright © 2017 AGA Institute. Published by Elsevier Inc. All

2017 EvidenceUpdates

70. Deprescribing versus continuation of chronic proton pump inhibitor use in adults. Full Text available with Trip Pro

Deprescribing versus continuation of chronic proton pump inhibitor use in adults. Proton pump inhibitors (PPIs) are a class of medications that reduce acid secretion and are used for treating many conditions such as gastroesophageal reflux disease (GERD), dyspepsia, reflux esophagitis, peptic ulcer disease, and hypersecretory conditions (e.g. Zollinger-Ellison syndrome), and as part of the eradication therapy for Helicobacter pylori bacteria. However, approximately 25% to 70% of people

2017 Cochrane

71. Clopidogrel and Proton Pump Inhibitor Use: A Review of the Evidence on Safety

Clopidogrel and Proton Pump Inhibitor Use: A Review of the Evidence on Safety Clopidogrel and Proton Pump Inhibitor Use: A Review of the Evidence on Safety | CADTH.ca Find the information you need Clopidogrel and Proton Pump Inhibitor Use: A Review of the Evidence on Safety Clopidogrel and Proton Pump Inhibitor Use: A Review of the Evidence on Safety Published on: March 14, 2017 Project Number: RC0874-000 - RD0036-000 Product Line: Research Type: Drug Report Type: Summary with Critical (...) Appraisal Result type: Report Question What are the harms of proton pump inhibitors used concomitantly with clopidogrel for patients requiring antiplatelet therapy following percutaneous coronary intervention? Key Message Although the findings across the studies were mixed, overall, the evidence favours clopidogrel antiplatelet therapy without PPIs. The evidence suggests that there are still some serious safety risks associated with the use of proton pump inhibitors (PPIs) with clopidogrel antiplatelet

2017 Canadian Agency for Drugs and Technologies in Health - Rapid Review

72. Proton pump inhibitors for functional dyspepsia. Full Text available with Trip Pro

Proton pump inhibitors for functional dyspepsia. Functional dyspepsia (FD or non-ulcer dyspepsia) is defined as continuous or frequently recurring epigastric pain or discomfort for which no organic cause can be found. Acid suppressive therapy, including proton pump inhibitors (PPIs), has been proposed as a therapeutic option in FD, but its efficacy remains controversial. While PPIs are generally considered safe and well tolerated, they have been associated with adverse events, especially (...) in the long term. For this reason, decisions on whether to initiate or continue PPI therapy should be made based on an appropriate clinical indication. Therefore, we conducted a systematic review to evaluate whether PPI therapy provides symptomatic relief in FD.To determine the efficacy of proton pump inhibitors in the improvement of global symptoms of dyspepsia and quality of life compared to placebo, H2 receptor antagonists or prokinetics, in people with functional dyspepsia.We searched in the following

2017 Cochrane

73. [Optimal long-term use of proton pump inhibitors]

[Optimal long-term use of proton pump inhibitors] Usage optimal à long terme des inhibiteurs de la pompe à protons [Optimal long-term use of proton pump inhibitors] Usage optimal à long terme des inhibiteurs de la pompe à protons [Optimal long-term use of proton pump inhibitors] Tremblay E, Tardif M Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database (...) . Citation Tremblay E, Tardif M. Usage optimal à long terme des inhibiteurs de la pompe à protons. [Optimal long-term use of proton pump inhibitors] Quebec: Institut national d'excellence en sante et en services sociaux (INESSS). 2016 Authors' conclusions Upon gathering information from good clinical practice recommendations and during multiple consultations, INESSS made the following observations: • Prescribing PPIs is unwarranted in many cases. • It will take more than clinical tools and training

2017 Health Technology Assessment (HTA) Database.

74. Proton Pump Inhibitors and Kidney Disease—GI Upset for the Nephrologist? Full Text available with Trip Pro

Proton Pump Inhibitors and Kidney Disease—GI Upset for the Nephrologist? Widely regarded as safe and effective, proton pump inhibitors (PPIs) are among the most commonly used medications in the world today. However, a spate of observational studies suggest an association between PPI use and adverse events, including infection, bone fracture, and dementia. This review details evidence linking the use of PPI therapy to the development of kidney disease, including early case reports of acute

2017 Kidney international reports

75. Efficacy of proton pump inhibitors plus mucoprotective agents for endoscopic submucosal dissection-derived ulcers: a systematic review and meta-analysis of randomized controlled trials

Efficacy of proton pump inhibitors plus mucoprotective agents for endoscopic submucosal dissection-derived ulcers: a systematic review and meta-analysis of randomized controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites

2017 PROSPERO

76. Proton pump inhibitors use and risk of dementia: systematic review and meta-analysis

Proton pump inhibitors use and risk of dementia: systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing

2017 PROSPERO

77. Proton pump inhibitor- and fluoroquinolone-based triple therapies for Helicobacter pylori eradication [Cochrane protocol]

Proton pump inhibitor- and fluoroquinolone-based triple therapies for Helicobacter pylori eradication [Cochrane protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence

2017 PROSPERO

78. Association of proton pump inhibitors with the risk of hepatic encephalopathy in liver cirrhosis: a systematic review and meta-analysis

Association of proton pump inhibitors with the risk of hepatic encephalopathy in liver cirrhosis: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2017 PROSPERO

79. Association between use of proton pump inhibitors and the risk of fundic gland polyps: a meta-analysis

Association between use of proton pump inhibitors and the risk of fundic gland polyps: a meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web

2017 PROSPERO

80. The risks of chronic kidney disease (CKD) and/or end stage kidney disease (ESRD) in patients taking proton pump inhibitors (PPIs) and/or H2 receptor antagonists (H2RAs)

The risks of chronic kidney disease (CKD) and/or end stage kidney disease (ESRD) in patients taking proton pump inhibitors (PPIs) and/or H2 receptor antagonists (H2RAs) Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation

2017 PROSPERO